Openbookopenbook
Equity
SMDPY
+0.0 · +0.00%
USD · PINK

Sumitomo Pharma Co. Ltd(SMDPY) Stock Analysis | Healthcare

USD --+0.00%
Reward43Moderate
Risk45Moderate
75%Data
Strong 24% profit margin
Value Trap
Market Cap:7.91Bn
ⓘ
Reward Rating
43
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
45
Moderate
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SMDPY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for SMDPY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Sumitomo Pharma Co. Ltd?

Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia.

SMDPY · Verdict

Moderate reward · moderate risk

SMDPY's standout is volatility; balance sheet and growth weigh on the picture.

Based on 88% data coverage

SMDPY · Verdict

What’s working & what to watch

Strengths 1

  • Volatility80/100

    Top decile vs peers

Watchouts 3

  • Balance sheet20/100

    Interest covered 2.3×

  • Growth28/100

    Rev -10.7% CAGR · earnings -25.2%

  • Cash flow45/100

    1% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is Sumitomo Pharma Co. Ltd?

Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 7.91B, and a P/E ratio of 6.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (43)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

RGEDFMid Cap / 7.9B market cap
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Compare
HIMSMid Cap / 7.9B market cap
Hims Hers Health Inc
Compare
ALKSMid Cap / 8.1B market cap
Alkermes Plc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap7.91B
P/E Ratio6.1606
Dividend YieldN/A
Beta0.449
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.